Skip to main content
OpenTrials
Completed

NCT Number: NCT05227404

Evaluation of Point-of-Care (EPOC) for COVID-19

EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Informed consent by the patient or the patient's legally authorized representative (LAR) for up to 4 fingersticks for POC testing and a blood draw for stored blood samples.
  • SARS-CoV-2 infection, documented by a nucleic acid test (NAT) or equivalent testing within 3 days prior to consent OR documented by NAT or equivalent testing more than 3 days prior to consent AND progressive disease suggestive of ongoing SARS-CoV-2 infection per the responsible investigator. (For non-NAT tests, only those deemed with equivalent specificity to NAT by the protocol team will be allowed. A central list of allowed non-NAT tests is maintained for TICO and that list will also be used for this protocol.)
  • Duration of symptoms attributable to COVID-19 ≤ 12 days per the responsible investigator.
  • Requiring admission for inpatient hospital acute medical care for clinical manifestations of COVID-19, per the responsible investigator, and NOT for purely public health or quarantine purposes.

Exclusion criteria

  • Prior receipt of SARS-CoV-2 hIVIG, convalescent plasma from a person who recovered from COVID-19, or SARS-CoV-2 nMAb within 6 months of the blood draws for testing as part of this protocol.
  • Disease severity beyond that of stratum 1 in the TICO trial. This includes the following conditions:
  • stroke
  • meningitis
  • encephalitis
  • myelitis
  • myocardial infarction
  • myocarditis
  • pericarditis
  • symptomatic congestive heart failure (CHF; New York Heart Association [NYHA] class III-IV)
  • arterial or deep venous thrombosis or pulmonary embolism
  • Current requirement for any of the following:
  • high-flow supplemental oxygen
  • non-invasive ventilation
  • invasive mechanical ventilation
  • extracorporeal membrane oxygenation
  • mechanical circulatory support
  • vasopressor therapy
  • commencement of renal replacement therapy at this admission (i.e., not patients on chronic renal replacement therapy).
  • In the opinion of the responsible investigator, any condition for which, participation would not be in the best interest of the participant or that could limit protocol specified assessments.

Treatment and study plan

LumiraDX

Diagnostic Test

Point-of-care test for SARS-CoV-2

RightSign

Diagnostic Test

Point-of-care test for SARS-CoV-2

Case Control

Diagnostic Test

Genscript assay performed on the plasma sample

Primary outcomes

  1. Test Results Comparison Between LumiraDx and GenScript

    Time frame: an average of 1 day

    LumiraDx test and GenScript assay are two ways to determine the presence of antibodies to SARS-CoV-2. This measure is a comparison to check agreement between the two tests' results. This is a comparison of the proportion of the positive tests. The comparison is made by looking at the difference of the two proportions obtained by the two tests, so the measure is unitless.

  2. Comparison of Results Obtained by RightSign and GenScript

    Time frame: an average of 1 day

    RightSign test and GenScript assay are two ways to determine the presence of antibodies to SARS-CoV-2. This measure is a comparison to check agreement between the two tests' results. This is a comparison of the proportion of the positive tests. The comparison is made by looking at the difference of the two proportions obtained by the two tests, so the measure is unitless.

Secondary outcomes

  1. LumiraDx Valid Test Frequency

    Time frame: an average of 1 day

    The frequency with which the LumiraDx test fails to give an unambiguous result

  2. RightSign Valid Test Frequency

    Time frame: an average of 1 day

    The frequency with wich the RightSign test fails to give an unambiguous result

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

Evaluation of the Feasibility and Reproducibility of 2 Point-of-Care Tests for SARS-Co-V-2 Antibodies (INSIGHT 017)

Acronym: (EPOC)

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Feb 7, 2022
Registry last updated
Dec 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.